Pulmonary Cell News Volume 8.45 | Nov 21 2019

TOP STORY

Derivation of Self-Renewing Lung Alveolar Epithelial Type II Cells from Human Pluripotent Stem Cells

Researchers provide a detailed protocol for the directed differentiation of human pluripotent stem cells into self-renewing alveolar epithelial type II-like cells that can be maintained for up to one year in culture as epithelial-only spheres without the need for supporting mesenchymal feeder cells. [Nat Protoc] Abstract

(Ranked by impact factor of the journal)

Airway Epithelial Regeneration Requires Autophagy and Glucose Metabolism

Investigators used small molecules, genetic loss-of-function, organoid cultures, and in vivo lung-injury models to show that autophagy was essential for maintaining the pool of airway stem-like vClub cells by promoting their proliferation during ovalbumin-induced acute inflammation. [Cell Death Dis] Full Article

Idebenone Has Preventative and Therapeutic Effects on Pulmonary Fibrosis via Preferential Suppression of Fibroblast Activity

Idebenone induced cell growth inhibition and cell death in LL29 cells at a lower concentration than in A549 cells, a feature that was not observed for other antioxidant molecules and two idiopathic pulmonary fibrosis drugs. [Cell Death Dis] Full Article

Cigarette Smoke Extract Modulates Pseudomonas aeruginosa Bacterial Load via USP25/HDAC11 Axis in Lung Epithelial Cells

Cigarette smoking extract-downregulated USP25/HDAC11 axis increased the bacterial load of P. aeruginosa in lung epithelial cells. [Am J Physiol Lung Cell Mol Physiol] Abstract

LUNG CANCER

The Deubiquitinase USP10 Regulates KLF4 Stability and Suppresses Lung Tumorigenesis

Forced expression of ubiquitin-specific peptidase 10 (USP10) remarkably increased Krüppel-like factor 4 (KLF4) protein level by blocking the latter degradation, whereas the depletion of USP10 promoted KLF4 degradation and thus enhanced tumorigenesis [Cell Death Differ] Abstract

Non-Genetic Intra-Tumor Heterogeneity Is a Major Predictor of Phenotypic Heterogeneity and Ongoing Evolutionary Dynamics in Lung Tumors

The authors analyzed intra-tumor heterogeneity in lung squamous cell carcinoma at the levels of genome, transcriptome, and tumor-immune interactions and histopathological characteristics by multi-region bulk and single-cell sequencing. [Cell Rep] Full Article | Graphical Abstract

Distinct Co-Acquired Alterations and Genomic Evolution during TKI Treatment in Non-Small-Cell Lung Cancer Patients with or without Acquired T790M Mutation

Chromosomal instability significantly increased during tyrosine kinase inhibitor (TKI) treatment in T790M-negative patients and was a candidate resistance mechanism to the first-generation TKIs. [Oncogene] Abstract

Transcriptome Dynamics of Alternative Splicing Events Revealed Early Phase of Apoptosis Induced by Methylparaben in H1299 Human Lung Carcinoma Cells

Scientists investigated the effect of methylparaben on cell cycle, apoptotic pathways, and changes in the transcriptome profiles in human lung cells. Their results demonstrate that treatment with methylparaben caused inhibition of cell growth. [Arch Toxicol] Abstract

PTBP1-Mediated Regulation of AXL mRNA Stability Plays a Role in Lung Tumorigenesis

Investigators showed that the RNA binding protein polypyrimidine tract-binding protein (PTBP)1 directly targeted the 5′-UTR of AXL mRNA in vitro and in vivo. [Sci Rep] Full Article

Subscribe to one of our other 19 science newsletters such as Cancer Stem Cell News & Human Immunology News.

Current Approaches in NSCLC Targeting K-RAS and EGFR

Epidermal growth factor receptor (EGFR) and Kirsten rat sarcoma viral oncogene homolog (K-RAS) are two of the main significant biomarkers for the management of non-small cell lung cancer (NSCLC). Mutations in these genes were associated with development and response to therapies. [Int J Mol Sci] Abstract

Visit our reviews page to see a complete list of reviews in the pulmonary cell research field.

Corbus Pharmaceuticals Completes Enrollment of Phase IIb Study of Lenabasum for Treatment of Cystic Fibrosis

Corbus Pharmaceuticals Holdings, Inc. announced the completion of patient enrollment in the Phase IIb study evaluating the efficacy and safety of lenabasum for the treatment of CF. [Corbus Pharmaceuticals Holdings, Inc.] Press Release

Roche Buying Promedior for $390 Million to Develop Drugs for Fibrotic Disease

Roche has agreed to pay $390 million upfront for a Lexington, Mass., biotech that has developed experimental drugs for fibrotic diseases, including a compound to treat a rare and fatal progressive lung disease. [STAT News] Editorial

Stephen Hahn, Trump’s FDA Nominee, Pledges ‘Bold Action’ on Vaping but Sidesteps Questions on Flavor Ban

President Trump’s nominee to lead the FDA, faced with a barrage of questions on Wednesday about his views on youth vaping, pledged “bold action” to address the crisis but demurred when asked directly by US senators whether he supported a wholesale ban on flavored e-cigarette products. [STAT News] Editorial

Foreign Interference Fears Prompt Guidelines for Australian Universities

New guidelines will help Australian universities protect themselves against foreign interference, says the country’s government. The advice follows concerns that foreign groups or governments, such as the government of China, might be seeking to instigate campus activities that are against Australia’s interests. [Nature News] Editorial

NEW Exosomes in Human Infectious Diseases Conference
March 5-8, 2020
Nassau, Bahamas

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Position – Obstructive Lung Disease (Karolinska Institutet)

PhD Student – Organ-on-Chip (Helmholtz Zentrum München)

Postdoctoral Fellow – Pulmonary Research (Universitätsklinikum Erlangen)

Postdoctoral Fellow – Lung Cancer Epigenomics (Icahn School of Medicine at Mount Sinai)

Postdoctoral Research Fellow – Small Cell Lung Cancer (University Hospital of Cologne)

PhD Studentship – Small Cell Lung Cancer (Cancer Research UK Manchester Institute)

Postdoctoral Research Fellow – Lung Development and Disease (Center for Regenerative Medicine)

Research Fellow – Lung Cancer (Dana-Farber Cancer Institute)

Faculty Position – Pulmonary and Critical Care Medicine (Mayo Clinic Comprehensive Cancer Center)

Research Scientist – Fibrosis (Gilead Sciences, Inc.)

Postdoctoral Fellowship – Lung Epithelium (Boston University)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Pulmonary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.